Rexahn Pharmaceuticals, Inc. (NYSE:RNN) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 1,087,401 shares, a growth of 44.4% from the September 15th total of 752,788 shares. Based on an average daily volume of 1,116,332 shares, the short-interest ratio is currently 1.0 days. Approximately 0.5% of the company’s stock are short sold.

A number of brokerages recently commented on RNN. Zacks Investment Research raised Rexahn Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 30th. FBR & Co reissued an “outperform” rating and issued a $3.00 price target on shares of Rexahn Pharmaceuticals in a report on Wednesday, October 5th.

Shares of Rexahn Pharmaceuticals (NYSE:RNN) traded down 2.3333% on Tuesday, reaching $0.2051. The company had a trading volume of 1,565,130 shares. Rexahn Pharmaceuticals has a 52-week low of $0.20 and a 52-week high of $0.52. The firm’s market capitalization is $43.75 million. The company has a 50-day moving average price of $0.24 and a 200-day moving average price of $0.27.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Rexahn Pharmaceuticals (NYSE:RNN) last posted its earnings results on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Equities research analysts forecast that Rexahn Pharmaceuticals will post ($0.07) EPS for the current fiscal year.

An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Vanguard Group Inc. increased its stake in shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent reporting period.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

5 Day Chart for NYSE:RNN

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.